Effect  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
diet  ||| S:10 E:15 ||| NN
and  ||| S:15 E:19 ||| CC
omega-3  ||| S:19 E:27 ||| FW
fatty  ||| S:27 E:33 ||| FW
acids  ||| S:33 E:39 ||| FW
in  ||| S:39 E:42 ||| FW
NAFLD  ||| S:42 E:48 ||| FW
Nonalcoholic  ||| S:48 E:61 ||| FW
fatty  ||| S:61 E:67 ||| FW
liver  ||| S:67 E:73 ||| FW
disease  ||| S:73 E:81 ||| FW
( ||| S:81 E:82 ||| -LRB-
NAFLD ||| S:82 E:87 ||| NNP
)  ||| S:87 E:89 ||| -RRB-
ranges  ||| S:89 E:96 ||| NNS
from  ||| S:96 E:101 ||| IN
simple  ||| S:101 E:108 ||| JJ
hepatic  ||| S:108 E:116 ||| JJ
steatosis  ||| S:116 E:126 ||| NN
to  ||| S:126 E:129 ||| TO
steatohepatitis  ||| S:129 E:145 ||| VB
( ||| S:145 E:146 ||| -LRB-
NASH ||| S:146 E:150 ||| NNP
)  ||| S:150 E:152 ||| -RRB-
and  ||| S:152 E:156 ||| CC
cirrhosis ||| S:156 E:165 ||| NN
.  ||| S:165 E:167 ||| .
The  ||| S:167 E:171 ||| DT
aim  ||| S:171 E:175 ||| NN
of  ||| S:175 E:178 ||| IN
this  ||| S:178 E:183 ||| DT
study  ||| S:183 E:189 ||| NN
is  ||| S:189 E:192 ||| VBZ
to  ||| S:192 E:195 ||| TO
test  ||| S:195 E:200 ||| VB
beneficial  ||| S:200 E:211 ||| JJ
effects  ||| S:211 E:219 ||| NNS
of  ||| S:219 E:222 ||| IN
omega-3  ||| S:222 E:230 ||| FW
fatty  ||| S:230 E:236 ||| FW
acids  ||| S:236 E:242 ||| FW
( ||| S:242 E:243 ||| -LRB-
DHA  ||| S:243 E:247 ||| NNP
130  ||| S:247 E:251 ||| CD
mg ||| S:251 E:253 ||| NN
,  ||| S:253 E:255 ||| ,
EPA  ||| S:255 E:259 ||| NNP
25  ||| S:259 E:262 ||| CD
mg ||| S:262 E:264 ||| CD
)  ||| S:264 E:266 ||| -RRB-
treatment  ||| S:266 E:276 ||| NN
in  ||| S:276 E:279 ||| IN
NAFLD ||| S:279 E:284 ||| NNP
,  ||| S:284 E:286 ||| ,
in  ||| S:286 E:289 ||| IN
a  ||| S:289 E:291 ||| DT
mouse  ||| S:291 E:297 ||| NN
model  ||| S:297 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
non-alcoholic  ||| S:306 E:320 ||| JJ
fatty  ||| S:320 E:326 ||| JJ
liver  ||| S:326 E:332 ||| NN
disease ||| S:332 E:339 ||| NN
.  ||| S:339 E:341 ||| .
As  ||| S:341 E:344 ||| IN
pretreatment ||| S:344 E:356 ||| NN
,  ||| S:356 E:358 ||| ,
50  ||| S:358 E:361 ||| CD
mice  ||| S:361 E:366 ||| NNS
were  ||| S:366 E:371 ||| VBD
fed  ||| S:371 E:375 ||| VBN
for  ||| S:375 E:379 ||| IN
one  ||| S:379 E:383 ||| CD
month  ||| S:383 E:389 ||| NN
with  ||| S:389 E:394 ||| IN
a  ||| S:394 E:396 ||| DT
high-fat  ||| S:396 E:405 ||| JJ
diet  ||| S:405 E:410 ||| NN
to  ||| S:410 E:413 ||| TO
induce  ||| S:413 E:420 ||| VB
NAFLD ||| S:420 E:425 ||| NNP
.  ||| S:425 E:427 ||| .
Then ||| S:427 E:431 ||| RB
,  ||| S:431 E:433 ||| ,
the  ||| S:433 E:437 ||| DT
mice  ||| S:437 E:442 ||| NNS
were  ||| S:442 E:447 ||| VBD
divided  ||| S:447 E:455 ||| VBN
in  ||| S:455 E:458 ||| IN
different  ||| S:458 E:468 ||| JJ
groups  ||| S:468 E:475 ||| NNS
according  ||| S:475 E:485 ||| VBG
to  ||| S:485 E:488 ||| TO
diet  ||| S:488 E:493 ||| VB
( ||| S:493 E:494 ||| -LRB-
normo-  ||| S:494 E:501 ||| NNP
or  ||| S:501 E:504 ||| CC
hypercaloric ||| S:504 E:516 ||| CD
) ||| S:516 E:517 ||| -RRB-
,  ||| S:517 E:519 ||| ,
with  ||| S:519 E:524 ||| IN
and  ||| S:524 E:528 ||| CC
without  ||| S:528 E:536 ||| IN
treatment  ||| S:536 E:546 ||| NN
with  ||| S:546 E:551 ||| IN
omega-3  ||| S:551 E:559 ||| CD
fatty  ||| S:559 E:565 ||| CD
acids ||| S:565 E:570 ||| NNS
,  ||| S:570 E:572 ||| ,
for  ||| S:572 E:576 ||| IN
another  ||| S:576 E:584 ||| DT
month ||| S:584 E:589 ||| NN
,  ||| S:589 E:591 ||| ,
forming  ||| S:591 E:599 ||| VBG
the  ||| S:599 E:603 ||| DT
post-treatment  ||| S:603 E:618 ||| JJ
group ||| S:618 E:623 ||| NN
.  ||| S:623 E:625 ||| .
The  ||| S:625 E:629 ||| DT
liver  ||| S:629 E:635 ||| NN
and  ||| S:635 E:639 ||| CC
blood  ||| S:639 E:645 ||| NN
samples  ||| S:645 E:653 ||| NNS
were  ||| S:653 E:658 ||| VBD
collected  ||| S:658 E:668 ||| VBN
for  ||| S:668 E:672 ||| IN
biochemical  ||| S:672 E:684 ||| NN
and  ||| S:684 E:688 ||| CC
histopathological  ||| S:688 E:706 ||| JJ
analysis ||| S:706 E:714 ||| NN
.  ||| S:714 E:716 ||| .
Biochemical  ||| S:716 E:728 ||| JJ
parameters  ||| S:728 E:739 ||| NNS
including ||| S:739 E:748 ||| VBG
:  ||| S:748 E:750 ||| :
glycemia ||| S:750 E:758 ||| CD
,  ||| S:758 E:760 ||| ,
total  ||| S:760 E:766 ||| JJ
cholesterol ||| S:766 E:777 ||| NN
,  ||| S:777 E:779 ||| ,
triglycerides ||| S:779 E:792 ||| NN
,  ||| S:792 E:794 ||| ,
uric  ||| S:794 E:799 ||| JJ
acid ||| S:799 E:803 ||| NN
,  ||| S:803 E:805 ||| ,
albumin ||| S:805 E:812 ||| NN
,  ||| S:812 E:814 ||| ,
total  ||| S:814 E:820 ||| JJ
plasma  ||| S:820 E:827 ||| JJ
antioxidant  ||| S:827 E:839 ||| JJ
capacity  ||| S:839 E:848 ||| NN
( ||| S:848 E:849 ||| -LRB-
TEAC ||| S:849 E:853 ||| NNP
)  ||| S:853 E:855 ||| -RRB-
was  ||| S:855 E:859 ||| VBD
measured  ||| S:859 E:868 ||| VBN
in  ||| S:868 E:871 ||| IN
serum ||| S:871 E:876 ||| NN
.  ||| S:876 E:878 ||| .
Glutathione  ||| S:878 E:890 ||| NNP
( ||| S:890 E:891 ||| -LRB-
GSH ||| S:891 E:894 ||| NNP
) ||| S:894 E:895 ||| -RRB-
,  ||| S:895 E:897 ||| ,
total  ||| S:897 E:903 ||| JJ
thiols  ||| S:903 E:910 ||| NN
and  ||| S:910 E:914 ||| CC
malonyldialdehyde  ||| S:914 E:932 ||| NNS
( ||| S:932 E:933 ||| -LRB-
MDA ||| S:933 E:936 ||| NNP
)  ||| S:936 E:938 ||| -RRB-
were  ||| S:938 E:943 ||| VBD
determined  ||| S:943 E:954 ||| VBN
in  ||| S:954 E:957 ||| IN
mouse  ||| S:957 E:963 ||| NN
liver  ||| S:963 E:969 ||| NN
homogenates ||| S:969 E:980 ||| NN
.  ||| S:980 E:982 ||| .
Mice  ||| S:982 E:987 ||| NNS
from  ||| S:987 E:992 ||| IN
post-treatment  ||| S:992 E:1007 ||| JJ
group ||| S:1007 E:1012 ||| NN
,  ||| S:1012 E:1014 ||| ,
on  ||| S:1014 E:1017 ||| IN
hypercaloric  ||| S:1017 E:1030 ||| JJ
diet  ||| S:1030 E:1035 ||| NN
with  ||| S:1035 E:1040 ||| IN
or  ||| S:1040 E:1043 ||| CC
without  ||| S:1043 E:1051 ||| IN
omega-3  ||| S:1051 E:1059 ||| CD
fatty  ||| S:1059 E:1065 ||| CD
acids  ||| S:1065 E:1071 ||| JJ
treatment ||| S:1071 E:1080 ||| NN
,  ||| S:1080 E:1082 ||| ,
had  ||| S:1082 E:1086 ||| VBD
medium  ||| S:1086 E:1093 ||| JJ
hepatopathy  ||| S:1093 E:1105 ||| NNS
( ||| S:1105 E:1106 ||| -LRB-
granular  ||| S:1106 E:1115 ||| NN
and  ||| S:1115 E:1119 ||| CC
vacuolar  ||| S:1119 E:1128 ||| JJ
degeneration  ||| S:1128 E:1141 ||| NN
of  ||| S:1141 E:1144 ||| IN
the  ||| S:1144 E:1148 ||| DT
hepatocytes ||| S:1148 E:1159 ||| NN
)  ||| S:1159 E:1161 ||| -RRB-
and  ||| S:1161 E:1165 ||| CC
hypertriglyceridemia ||| S:1165 E:1185 ||| NN
.  ||| S:1185 E:1187 ||| .
Omega-3  ||| S:1187 E:1195 ||| NNP
fatty  ||| S:1195 E:1201 ||| VBD
acid  ||| S:1201 E:1206 ||| JJ
treatment  ||| S:1206 E:1216 ||| NN
lowered  ||| S:1216 E:1224 ||| VBD
the  ||| S:1224 E:1228 ||| DT
rise  ||| S:1228 E:1233 ||| NN
of  ||| S:1233 E:1236 ||| IN
triglycerides  ||| S:1236 E:1250 ||| NNS
( ||| S:1250 E:1251 ||| -LRB-
p  ||| S:1251 E:1252 ||| CD
< ||| S:1252 E:1253 ||| SYM
0.03 ||| S:1253 E:1257 ||| CD
) ||| S:1257 E:1258 ||| -RRB-
,  ||| S:1258 E:1260 ||| ,
glycemia  ||| S:1260 E:1269 ||| NNS
( ||| S:1269 E:1270 ||| -LRB-
p  ||| S:1270 E:1271 ||| CD
< ||| S:1271 E:1272 ||| SYM
0.01 ||| S:1272 E:1276 ||| CD
)  ||| S:1276 E:1278 ||| -RRB-
and  ||| S:1278 E:1282 ||| CC
cholesterol  ||| S:1282 E:1294 ||| NN
( ||| S:1294 E:1295 ||| -LRB-
p  ||| S:1295 E:1296 ||| CD
< ||| S:1296 E:1297 ||| SYM
0.02 ||| S:1297 E:1301 ||| CD
)  ||| S:1301 E:1303 ||| -RRB-
in  ||| S:1303 E:1306 ||| IN
serum  ||| S:1306 E:1312 ||| NN
and  ||| S:1312 E:1316 ||| CC
MDA  ||| S:1316 E:1320 ||| NNP
level  ||| S:1320 E:1326 ||| NN
of  ||| S:1326 E:1329 ||| IN
the  ||| S:1329 E:1333 ||| DT
liver  ||| S:1333 E:1339 ||| NN
( ||| S:1339 E:1340 ||| -LRB-
p  ||| S:1340 E:1341 ||| CD
< ||| S:1341 E:1342 ||| SYM
0.05 ||| S:1342 E:1346 ||| CD
) ||| S:1346 E:1347 ||| -RRB-
.  ||| S:1347 E:1349 ||| .
Mice  ||| S:1349 E:1354 ||| NNS
from  ||| S:1354 E:1359 ||| IN
post-treatment  ||| S:1359 E:1374 ||| JJ
group ||| S:1374 E:1379 ||| NN
,  ||| S:1379 E:1381 ||| ,
on  ||| S:1381 E:1384 ||| IN
normocaloric  ||| S:1384 E:1397 ||| JJ
diet  ||| S:1397 E:1402 ||| NN
with  ||| S:1402 E:1407 ||| IN
or  ||| S:1407 E:1410 ||| CC
without  ||| S:1410 E:1418 ||| IN
omega-3  ||| S:1418 E:1426 ||| CD
fatty  ||| S:1426 E:1432 ||| JJ
acid  ||| S:1432 E:1437 ||| NN
had  ||| S:1437 E:1441 ||| VBD
different  ||| S:1441 E:1451 ||| JJ
histopathological  ||| S:1451 E:1469 ||| NN
and  ||| S:1469 E:1473 ||| CC
biochemical  ||| S:1473 E:1485 ||| JJ
results ||| S:1485 E:1492 ||| NNS
.  ||| S:1492 E:1494 ||| .
Those  ||| S:1494 E:1500 ||| DT
with  ||| S:1500 E:1505 ||| IN
normocaloric ||| S:1505 E:1517 ||| CD
/ ||| S:1517 E:1518 ||| CD
normolipidic  ||| S:1518 E:1531 ||| JJ
diet  ||| S:1531 E:1536 ||| NN
and  ||| S:1536 E:1540 ||| CC
omega-3  ||| S:1540 E:1548 ||| CD
fatty  ||| S:1548 E:1554 ||| CD
acids  ||| S:1554 E:1560 ||| JJ
treatment  ||| S:1560 E:1570 ||| NN
had  ||| S:1570 E:1574 ||| VBD
reversed  ||| S:1574 E:1583 ||| VBN
liver  ||| S:1583 E:1589 ||| JJ
histopathological  ||| S:1589 E:1607 ||| JJ
results  ||| S:1607 E:1615 ||| NNS
from  ||| S:1615 E:1620 ||| IN
NASH  ||| S:1620 E:1625 ||| NNP
to  ||| S:1625 E:1628 ||| TO
normal  ||| S:1628 E:1635 ||| JJ
aspect  ||| S:1635 E:1642 ||| NN
and  ||| S:1642 E:1646 ||| CC
had  ||| S:1646 E:1650 ||| VBD
the  ||| S:1650 E:1654 ||| DT
best  ||| S:1654 E:1659 ||| RBS
metabolic  ||| S:1659 E:1669 ||| JJ
parameters  ||| S:1669 E:1680 ||| JJ
results ||| S:1680 E:1687 ||| NNS
.  ||| S:1687 E:1689 ||| .
In  ||| S:1689 E:1692 ||| IN
conclusion ||| S:1692 E:1702 ||| NN
,  ||| S:1702 E:1704 ||| ,
omega-3  ||| S:1704 E:1712 ||| FW
fatty  ||| S:1712 E:1718 ||| FW
acids  ||| S:1718 E:1724 ||| FW
treatment  ||| S:1724 E:1734 ||| NN
associated  ||| S:1734 E:1745 ||| VBN
with  ||| S:1745 E:1750 ||| IN
a  ||| S:1750 E:1752 ||| DT
normocaloric ||| S:1752 E:1764 ||| FW
/ ||| S:1764 E:1765 ||| FW
normolipidic  ||| S:1765 E:1778 ||| FW
diet  ||| S:1778 E:1783 ||| FW
has  ||| S:1783 E:1787 ||| VBZ
hepatoprotective  ||| S:1787 E:1804 ||| JJ
action  ||| S:1804 E:1811 ||| NN
in  ||| S:1811 E:1814 ||| IN
nonalcoholic  ||| S:1814 E:1827 ||| JJ
fatty  ||| S:1827 E:1833 ||| JJ
liver  ||| S:1833 E:1839 ||| NN
disease ||| S:1839 E:1846 ||| NN
.  ||| S:1846 E:1848 ||| .
